CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells $120,897.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This represents a 3.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $42.12 on Friday. The business’s fifty day moving average price is $43.06 and its 200-day moving average price is $45.58. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $75.91. The stock has a market capitalization of $3.61 billion, a PE ratio of -9.64 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRSP. Wood Tarver Financial Group LLC purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $30,000. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter worth about $40,000. Ameriflex Group Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at about $36,000. Darwin Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics during the third quarter valued at about $43,000. Finally, Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth about $39,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRSP has been the subject of several analyst reports. Morgan Stanley increased their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. Finally, The Goldman Sachs Group cut their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.